Biotechnology
Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics
SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bisp...
2024-10-09 23:00
1312
Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a strategic collaboration with OverT Bio, aNew York-based biotechnology company. The collaboration will focus on developing ne...
2024-10-09 20:00
1145
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ -- Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. andOSAKA University Venture Capital, with participation from sev...
2024-10-09 15:23
1234
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...
2024-10-09 13:38
1583
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...
2024-10-09 13:32
1281
Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking
TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO:Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a master agreement signed on April 22, 2024 by Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:...
2024-10-09 10:00
1343
AWAK Transforms into Vivance, Unveiling a New Brand Identity
SINGAPORE, Oct. 9, 2024 /PRNewswire/ -- AWAK Technologies, a pioneer in innovative kidney care is excited to announce its rebranding toVivance. The name, derived from 'viva' and 'advance', embodies vitality and progress - hallmarks of the company's commitment to revolutionizing kidney health. AW...
2024-10-09 08:00
1696
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-10-08 20:30
3136
Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
* SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology. * With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, including those for pneumoniae and typhoid. * The ...
2024-10-08 20:00
1502
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a glo...
2024-10-08 20:00
1388
MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections
FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused byMycobacterium abscessus (Mab),...
2024-10-08 13:38
1040
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK...
2024-10-08 10:26
1585
Sciwind Biosciences Announces Oral Presentation on Oral GLP-2 Research Progress at the 32nd United European Gastroenterology Week (UEG Week 2024)
BEIJING and HANGZHOU, China, Oct. 7, 2024 /PRNewswire/ -- The 32nd United European Gastroenterology Week (UEG Week 2024) will take place inVienna, Austria , fromOctober 12 to 15, 2024. UEG Week is the largest gastroenterology conference inEurope and one of the leading meetings worldwide. It brings...
2024-10-08 10:00
1322
MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy
SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead a global clinical study to evaluate the therapeutic poten...
2024-10-08 08:00
1440
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2024-10-08 08:00
1767
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of68Ga-PSMA-11[1] injection) to select patients for...
2024-10-08 04:00
1719
The U.S. Fish and Wildlife Service Rejects Petition to List Long-Tailed Macaques Under the Endangered Species Act
WASHINGTON, Oct. 8, 2024 /PRNewswire/ -- On October 7, 2024, the U.S. Fish and Wildlife Service ("USFWS" or "the Service") declined to accept a petition filed by People for the Ethical Treatment of Animals (PETA) and other advocacy groups to list long-tailed macaque ("LTM") monkeys (Macaca fascic...
2024-10-08 03:31
1456
GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials
PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ -- GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), andAllterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candi...
2024-10-08 00:00
1244
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting
SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
2024-10-07 13:14
1861
Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development
HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutic...
2024-10-04 13:03
5606
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 303 media titles]
2024-12-27 13:17
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 253 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 245 media titles]
2024-12-25 15:45Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
[Picked up by 239 media titles]
2024-12-27 11:24
